focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of MYCELX property in Duluth, USA

18 Feb 2021 07:00

RNS Number : 5489P
MyCelx Technologies Corporation
18 February 2021
 

18 February 2021

 

MYCELX Technologies Corporation (AIM: MYX)

("MYCELX" or the "Company")

 

Sale of MYCELX property in Duluth, USA

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water technology company providing patented solutions for the Oil and Gas market and commercial industrial markets worldwide, announces the sale of its building in Duluth, Georgia, USA. This sale will enable the Company to right-size its office space needs across its three operating locations. The Company will receive a cash consideration of $5.4 million.

 

The Company has a debt obligation of circa $2.62 million on the property, so the net cash proceeds are expected to be in the range of $2.78 million. The current net book value of the property is $2.87 million, so MYCELX will recognize a financial gain of approximately $2.53 million.

 

When the building was originally purchased, the Company's engineering and business development capability was based in Duluth. However, now the Company has other offices across the globe and subsequently, personnel have relocated to these locations resulting in vacant office space.

 

MYCELX plans to convert the equity in the building into cash for working capital purposes and the team will relocate to another office and manufacturing property nearby that will better suit its needs and footprint. The sale of the property is in line with the Company's cost reduction strategy, reducing the overall cost of its office space and disposing of excess capacity.

 

The sale of the property to Angkawijana, L.L.C. is subject to certain typical completion conditions to closing. Post transaction, the Company expects to have circa $6 million of cash and cash equivalents on the balance sheet. The transaction is expected to close within the next 30 days.

 

MYCELX has historically had no profits/losses attributable to its Duluth property.

 

MYCELX recently applied for and received a second $400,000 forgivable loan from the Payroll Protection Program administered by the US Small Business Administration. The funds will be put towards maintaining payroll and other corporate purposes.

 

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and broker)

Henry Fitzgerald-O'Connor

Georgina McCooke

 

Tel: +44 20 7523 8150

Celicourt

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISGLGDDLDBDGBI
Date   Source Headline
4th Mar 20161:25 pmRNSHolding(s) in Company
4th Mar 20167:00 amRNSTrading Update
11th Jan 20165:30 pmRNSHolding(s) in Company
29th Dec 20152:23 pmRNSHolding(s) in Company
18th Dec 201510:13 amRNSHolding(s) in Company
15th Dec 20155:25 pmRNSHolding(s) in Company
15th Dec 20155:24 pmRNSHolding(s) in Company
11th Dec 20157:00 amRNSTrading Update
3rd Dec 201511:33 amRNSBlocklisting Interim Review
1st Oct 20157:00 amRNSProgress Update on Trials
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.